Emily is a former editorial intern at Spectrum and a graduate student in New York University’s Science, Health & Environmental Reporting Program. Previously, Emily worked on aging research in Boston, Massachusetts. She has a B.A. in chemistry from Williams College in Williamstown, Massachusetts.
Emily Harris
Former news intern
Spectrum
From this contributor
Prenatal exposures; Angelman trial suspension; autistic adult well-being
This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.
Prenatal exposures; Angelman trial suspension; autistic adult well-being
By
Emily Harris
17 July 2023 | 4 min read
Null and Noteworthy: Modified MRI; father findings
This month’s newsletter tackles null findings from an attempted replication of a “revolutionary” MRI approach and an analysis of family genetics.
Null and Noteworthy: Modified MRI; father findings
By
Emily Harris
22 June 2023 | 4 min read
Null and Noteworthy: Reinforcing rigor; medication medley
This month’s newsletter highlights findings on the use of three medication types during pregnancy.
Null and Noteworthy: Reinforcing rigor; medication medley
By
Emily Harris
14 December 2022 | 4 min read
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
By
Emily Harris
10 November 2022 | 5 min read
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
Parents’ health, treatment dosages and sensory perception feature in this month’s crop of null and replicated results.
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
By
Emily Harris
13 October 2022 | 5 min read
Explore more from The Transmitter
Dose, scan, repeat: Tracking the neurological effects of oral contraceptives
We know little about how the brain responds to oral contraceptives, despite their widespread use. I am committed to changing that: I scanned my brain 75 times over the course of a year and plan to make my data openly available.
Dose, scan, repeat: Tracking the neurological effects of oral contraceptives
We know little about how the brain responds to oral contraceptives, despite their widespread use. I am committed to changing that: I scanned my brain 75 times over the course of a year and plan to make my data openly available.
By
Carina Heller
20 January 2025 | 7 min read
Cracking the code of the extracellular matrix
Despite evidence for a role in plasticity and other crucial functions, many neuroscientists still view these proteins as “brain goop.” The field needs technical advances and a shift in scientific thinking to move beyond this outdated perspective.
Cracking the code of the extracellular matrix
Despite evidence for a role in plasticity and other crucial functions, many neuroscientists still view these proteins as “brain goop.” The field needs technical advances and a shift in scientific thinking to move beyond this outdated perspective.
By
Anna Victoria Molofsky
17 January 2025 | 5 min read
Huntington’s disease gene variants past a certain size poison select cells
The findings—providing “the next step in the whole pathway”—help explain the disease’s late onset and offer hope that it has an extended therapeutic window.
Huntington’s disease gene variants past a certain size poison select cells
The findings—providing “the next step in the whole pathway”—help explain the disease’s late onset and offer hope that it has an extended therapeutic window.
By
Angie Voyles Askham
16 January 2025 | 6 min read